/Charlotte Caldwell Calls for NHS Cannabis Prescription Reform as TRACD Unveils New Survey
– Charlotte Caldwell advocates for a stronger pathway to NHS cannabis treatment for chronic patients.
– Eight years post-Billy Caldwell’s pivotal case, she emphasizes the need for clinical trials and patient-centered care.
– TRACD launches a survey to gather real experiences from cannabis users, aiming to inform policy.
In a powerful call to action, Charlotte Caldwell, the mother of cannabis campaigner Billy Caldwell, is urging the UK government and cannabis industry to transform a recent legal victory into reliable treatment access for vulnerable and chronically ill patients through the NHS. Ahead of the eighth anniversary of the law change that enabled medicinal cannabis prescriptions, Caldwell is advocating for increased investment in clinical trials and a focus on patient care.
Reflecting on her son’s harrowing experience, Caldwell recalled, “In June 2018, I watched Billy become desperately ill after his lifesaving medicine was confiscated at Heathrow. While my son lay in hospital, the medicine we had fought to bring home was being held just miles away in the vaults of the Home Office. No mother should have to endure that.”
Caldwell expressed her disillusionment with the current state of medicinal cannabis access, stating, “When the law changed that November, I believed other patients would finally have a proper route to treatment. Eight years later, we must ask a difficult question: have we built a prescription market without building an adequate pathway to NHS care?”
She argued that while the number of private prescriptions has grown, it should not be misconstrued as progress for NHS patients. “Patients cannot put illness on hold. They cannot wait indefinitely for research, affordable treatment or the reassurance that their medicine will be available next month,” she emphasized.
Following the landmark changes in November 2018 that allowed specialist doctors to prescribe cannabis-based products, Caldwell is now challenging the cannabis industry to invest in the necessary trials to provide evidence on safety and effectiveness. “Another product on a private prescription list is not, by itself, another step towards NHS access,” she asserted.
Caldwell insists that the industry must prioritize research to determine effective treatments for patients. She stated, “Where is the commitment to finding out which medicines work, for which patients, at what dose and with what risks? Industry must invest in that work.”
Additionally, she is advocating for a clearer distinction between prescription treatments and adult-use cannabis regulations. Under her initiative TRACD – Transparent, Regulated Adult-use Controlled Data – she is proposing a controlled pilot to gather essential data on public health and consumer safety related to cannabis use.
“I believe we cannot put prescription cannabis care on a sound footing while avoiding an honest conversation about adult use,” Caldwell remarked. “Patients need treatment based on clinical need. Adults seeking cannabis for non-medical reasons need a separate policy discussion.”
To further the conversation and collect valuable insights, TRACD has launched a comprehensive cannabis policy research survey aimed at adults who have consumed or purchased cannabis in the past year. This initiative seeks to gather anonymized data from a variety of users, including those with prescriptions and those who have obtained cannabis through the illicit market.
“We need to hear what people are actually experiencing, not simply what looks reassuring in a sales pitch or sounds comfortable in a political debate,” Charlotte stated. She encouraged eligible participants to share their stories, asserting that “silence will not improve patient care. Assumptions will not build better policy.”
This survey aims to foster a more informed dialogue surrounding cannabis policies and ultimately drive improvements in patient care and legislative action.